Chronic Plaque Psoriasis Market Expected to rise, 2034 | Dermavant Sciences, Pfizer, Arcutis Biotherapeutics, BMS, Merck, UCB Pharma, Arbor Pharmaceuticals, Dr. Reddy's Laboratories, Kadmon Pharmaceut

The Chronic Plaque Psoriasis market growth is driven by factors like increase in the prevalence of Chronic Plaque Psoriasis, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Chronic Plaque Psoriasis market report [https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Chronic Plaque Psoriasis market size, share, Chronic Plaque Psoriasis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Chronic Plaque Psoriasis market size growth forward.

Some of the key highlights from the Chronic Plaque Psoriasis Market Insights Report:

*
Several key pharmaceutical companies, including Dermavant Sciences, Pfizer, Arcutis Biotherapeutics, BMS, Merck, UCB Pharma, Arbor Pharmaceuticals, Dr. Reddy's Laboratories, Kadmon Pharmaceuticals, Boehringer Ingelheim, Akros Pharma, Affibody AB, and others, are developing novel products to improve the Chronic Plaque Psoriasis treatment outlook.

*
In 2023, the Chronic Plaque Psoriasis market in the United States was valued at approximately USD 14,000 million and is projected to grow at a CAGR of 2.8% over the forecast period (2024-2034).

*
Among the 7MM, the U.S. recorded the highest number of diagnosed chronic plaque psoriasis cases in 2023, with around 6.4 million cases. This figure is expected to rise during the forecast period. Approximately 90% of psoriasis patients are affected by plaque psoriasis (psoriasis vulgaris), characterized by well-defined round or oval plaques covered with silvery-white scales.

*
In December 2024, Celltrion announced that its biosimilar Ustekinumab-stba (Steqeyma) had received FDA approval for both subcutaneous injection and intravenous infusion. The approval covers its use in treating adults and children with plaque psoriasis and psoriatic arthritis, as well as adults with Crohn's disease and ulcerative colitis.

*
In October 2023, the FDA approved BIMZELX (bimekizumab) for moderate to severe plaque psoriasis in adults eligible for systemic therapy or phototherapy. It is the first IL-17A and IL-17F inhibitor approved for this indication.

*
Biologic drugs have revolutionized plaque psoriasis treatment by targeting specific immune system components responsible for the disease, providing effective symptom control. Leading therapies in this segment include adalimumab, etanercept, ustekinumab, secukinumab, and ixekizumab.

*
The pipeline also includes promising candidates such as ME3183 (Meiji Seika Pharma), SGX302 (Soligenix), and TAK-279 (Takeda), signaling continued advancements in treatment options.

*
As per DelveInsight analysis, the Chronic Plaque Psoriasis market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Chronic Plaque Psoriasis Market Landscape [https://www.delveinsight.com/sample-request/chronic-plaque-psoriasis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Chronic Plaque Psoriasis Overview

Chronic plaque psoriasis is a long-lasting autoimmune skin disorder marked by raised, red, and scaly patches commonly found on the elbows, knees, scalp, and lower back. These plaques form due to accelerated skin cell turnover, resulting in a buildup of cells on the skin's surface. While the exact cause is unclear, the condition arises from a combination of genetic and environmental factors, with the immune system mistakenly targeting healthy skin cells. Although incurable, it can be managed with treatments aimed at reducing inflammation and slowing skin cell production.

Diagnosis is primarily clinical, based on the characteristic presentation of well-defined, erythematous plaques with silvery scales in common locations like the elbows, knees, and scalp. Physicians also review the patient's medical history, including family history and potential triggers such as stress or infections. While laboratory tests are rarely needed, a skin biopsy may be conducted in atypical cases to rule out other skin conditions. Additionally, physicians evaluate for comorbidities such as psoriatic arthritis, which can influence treatment plans.

Do you know the treatment paradigms for different countries? Download our Chronic Plaque Psoriasis Market Sample Report [https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Chronic Plaque Psoriasis Epidemiology Insights

*
In 2023, the United States had the highest prevalence of chronic plaque psoriasis among the 7MM, with approximately 6.4 million cases, a number expected to rise during the forecast period. Of these cases, nearly 80% were classified as mild in severity.

Chronic Plaque Psoriasis Epidemiology Segmentation

DelveInsight's Chronic Plaque Psoriasis market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Chronic Plaque Psoriasis historical patient pools and forecasted Chronic Plaque Psoriasis patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Chronic Plaque Psoriasis Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

*
Chronic Plaque Psoriasis Prevalence

*
Age-Specific Chronic Plaque Psoriasis Prevalence

*
Gender-Specific Chronic Plaque Psoriasis Prevalence

*
Diagnosed and Treatable Cases of Chronic Plaque Psoriasis

Visit for more @ Chronic Plaque Psoriasis Epidemiological Insights [https://www.delveinsight.com/sample-request/chronic-plaque-psoriasis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Chronic Plaque Psoriasis Market Outlook

Psoriasis is a chronic, relapsing condition that often necessitates long-term management, with treatment decisions shaped by disease severity, comorbidities, and access to healthcare. Patients are typically classified as having either mild or moderate-to-severe psoriasis. Mild cases are generally managed with topical treatments such as glucocorticoids, vitamin D analogs, and phototherapy, whereas moderate-to-severe cases often require systemic therapies, including biologics.

Biologics, such as TNF inhibitors (e.g., adalimumab) and interleukin-targeting agents (e.g., ustekinumab, secukinumab), have become highly effective options, particularly when conventional treatments are ineffective or unsuitable. Although biosimilars are available, their adoption-especially for infliximab-has been relatively slow in the U.S. Research indicates treatment rates for psoriasis remain around 50-60%, with oral therapies gaining popularity in recent years. Adalimumab is frequently used across multiple lines of therapy, reflecting its versatility and efficacy.

Chronic Plaque Psoriasis Marketed Drugs

*
TALTZ (ixekizumab): Eli Lilly and Company

*
SILIQ (brodalumab): AstraZeneca/Bausch Health

Chronic Plaque Psoriasis Emerging Drugs

*
TAK-279: Takeda

*
ME3183: Meiji Seika Pharma

*
SGX302: Soligenix

Chronic Plaque Psoriasis Key Companies

*
Dermavant Sciences, Pfizer, Arcutis Biotherapeutics, BMS, Merck, UCB Pharma, Arbor Pharmaceuticals, Dr. Reddy's Laboratories, Kadmon Pharmaceuticals, Boehringer Ingelheim, Akros Pharma, Affibody AB, and others

For more information, visit Chronic Plaque Psoriasis Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Chronic Plaque Psoriasis Market Report:

*
11 Years Forecast

*
7MM Coverage

*
Descriptive overview of Chronic Plaque Psoriasis, causes, signs and symptoms, diagnosis, treatment

*
Comprehensive insight into Chronic Plaque Psoriasis epidemiology in the 7MM

*
Chronic Plaque Psoriasis marketed and emerging therapies

*
Chronic Plaque Psoriasis companies

*
Chronic Plaque Psoriasis market drivers and barriers

Table of Contents:

1 Chronic Plaque Psoriasis Market Key Comprehensive Insights

2 Chronic Plaque Psoriasis Market Report Introduction

3 Competitive Intelligence Analysis for Chronic Plaque Psoriasis

4 Chronic Plaque Psoriasis Market Analysis Overview at a Glance

5 Executive Summary of Chronic Plaque Psoriasis

6 Chronic Plaque Psoriasis Epidemiology and Market Methodology

7 Chronic Plaque Psoriasis Epidemiology and Patient Population

8 Chronic Plaque Psoriasis Patient Journey

9 Chronic Plaque Psoriasis Treatment Algorithm, Chronic Plaque Psoriasis Current Treatment, and Medical Practices

10 Key Endpoints in Chronic Plaque Psoriasis Clinical Trials

11 Chronic Plaque Psoriasis Marketed Therapies

12 Chronic Plaque Psoriasis Emerging Therapies

13 Chronic Plaque Psoriasis: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Chronic Plaque Psoriasis

16 Chronic Plaque Psoriasis Market Key Opinion Leaders Reviews

18 Chronic Plaque Psoriasis Market Drivers

19 Chronic Plaque Psoriasis Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Chronic Plaque Psoriasis Epidemiology 2034

DelveInsight's "Chronic Plaque Psoriasis - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Chronic Plaque Psoriasis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Chronic Plaque Psoriasis Pipeline 2024

"Chronic Plaque Psoriasis Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Plaque Psoriasis market. A detailed picture of the Chronic Plaque Psoriasis pipeline landscape is provided, which includes the disease overview and Chronic Plaque Psoriasis treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-plaque-psoriasis-market-expected-to-rise-2034-dermavant-sciences-pfizer-arcutis-biotherapeutics-bms-merck-ucb-pharma-arbor-pharmaceuticals-dr-reddys-laboratories-kadmon-pharmaceut]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.